title: Canadian access to hormonal contraceptive drug choices.
abstract: On October 29, 2002, Health Canada issued Guidance for Industry: Clinical Development of Steroidal Contraceptives Used by Women. The original draft of this guideline, published July 4, 2001, included recommendations for clinical trials in excess of those required in Europe and the United States. The proposed requirements, which reflected Health Canada's views, had the potential to discourage contraceptive research in Canada and to block registration of new products. To evaluate the impact of Canada's hormonal contraceptive regulation, a comparative analysis of the availability of products in various countries was performed, along with an evaluation of the time required from submission to approval of a new drug. Women in Canada have access to 35% of the contraceptive products available worldwide and to 37% of the hormonal contraceptives available worldwide, compared with 58% and 59% respectively, in the United States; 52% and 54% respectively, in the United Kingdom; 44% and 54%, respectively, in France; and 44% and 50% respectively, in Sweden. Regarding the more recent contraceptive products available worldwide, women in Denmark have the most choices (67% of available products), whereas women in Canada have the least (only 22% of available products). Eleven of 12 oral contraceptive products recently approved in other countries have either not been submitted for approval in Canada or remain in the Canadian regulatory process. Although the time-to-approval period in Canada, for drugs in general, is 6 months longer than in the United States, the mean lag time for 6 contraceptive products is 29.6 months as of January 1, 2004, and no oral contraceptives have been approved in Canada since 1997.
authors.affiliation: Faculty of Pharmacy, University of Toronto,Toronto ON.
authors.forename: Dianne
authors.initials: D
authors.lastname: Azzarello
authors.forename: John
authors.initials: J
authors.lastname: Collins
mesh_terms: D002170:Canada; D003271:Contraceptive Agents, Female / Q000009:adverse effects / Q000600:supply & distribution*; D003278:Contraceptives, Oral, Hormonal / Q000009:adverse effects / Q000600:supply & distribution; D017277:Drug Approval; D015507:Drugs, Investigational; D005260:Female; D006801:Humans; D007880:Legislation, Drug; D012449:Safety
chemical_list: D003271:Contraceptive Agents, Female; D003278:Contraceptives, Oral, Hormonal; D015507:Drugs, Investigational